Massachusetts Medical Society: Question 2

Question 2

 

Question:

 

What is the recommended antiplatelet regimen for patients who require primary prevention of cardiovascular events?

 

 

 

Answers

Answer:

aspirin alone, at 81 mg/day
 

 

Correct Answer? 

 

Explanation:

Correct. Results of multiple clinical trials show that, as compared to placebo, aspirin reduces the risk of total cardiovascular events by 10%, driven largely by a reduction in nonfatal myocardial infarction. Doses over 81 mg/day increase the risk of bleeding without a countervailing increase in preventive efficacy.

 

Answers

Answer:

clopidogrel (Plavix) alone
 

 

Correct Answer? 

 

Explanation:

Incorrect. No trials have evaluated clopidogrel alone for the primary prevention of vascular events.

 

Answers

Answer:

aspirin and clopidogrel in combination
 

 

Correct Answer? 

 

Explanation:

Incorrect. The CHARISMA trial found no additional benefit of combining clopidogrel and aspirin compared to aspirin alone for primary prevention of cardiovascular events.

 

Answers

Answer:

prasugrel (Effient) alone
 

 

Correct Answer? 

 

Explanation:

Incorrect. No trials have evaluated prasugrel alone for the primary prevention of vascular events.

 

 

Format:

Radio buttons (single select)

 

Share on Facebook
Facebook logoLinkedInYouTube logoInstagramThreads

Copyright © 2025. Massachusetts Medical Society, 860 Winter Street, Waltham Woods Corporate Center, Waltham, MA 02451-1411

(781) 893-4610 | General Support: (617) 841-2925 or support@mms.org